Hippo includes a full set of CQC (Care Quality Commission) monitoring indicators designed to help practices meet clinical safety and medicines management requirements.
These indicators track whether key safety checks (like blood tests, kidney function, weight, and reviews) have been completed for patients on high-risk or regularly monitored medicines.
You can use them in Recall Campaigns to automate patient invitations or view them in Indicator Performance to track compliance.
💊 Medication Monitoring Indicators
CQCDOAC000–CQCDOAC007 — DOAC Monitoring
These indicators help ensure safe prescribing for patients on DOACs by checking their weight, renal function, and blood test results.
Indicator | Description | What It Checks |
CQCDOAC000 | Weight – patients on DOAC | Weight recorded in the last 12 months (needed for CrCl dosing). |
CQCDOAC001 | CrCl ever recorded | A creatinine clearance has been calculated at least once. |
CQCDOAC001A | Serum creatinine ever recorded | A serum creatinine has been taken at least once. |
CQCDOAC001B | CrCl ever, with valid weight + creatinine | CrCl recorded, and weight in the last 12 months, and a serum creatinine on file. |
CQCDOAC002 | Annual CrCl | Creatinine clearance in the last 12 months. |
CQCDOAC002A | Annual serum creatinine | Serum creatinine in the last 12 months. |
CQCDOAC002B | Annual CrCl, with valid weight + creatinine | CrCl in the last 12 months, and weight in the last 12 months, and serum creatinine in the last 12 months. |
CQCDOAC003 | 3-month CrCl – CKD4/5 | CrCl in the last 3 months for patients with CKD stage 4 or 5. |
CQCDOAC003A | 3-month creatinine – CKD4/5 | Serum creatinine in the last 3 months for patients with CKD stage 4 or 5. |
CQCDOAC003B | 3-month CrCl – CKD4/5, with valid weight + creatinine | CrCl in the last 3 months, plus weight in the last 12 months and serum creatinine in the last 3 months. |
CQCDOAC004 | 6-month CrCl – CKD3 | CrCl in the last 6 months for patients with CKD stage 3. |
CQCDOAC004A | 6-month creatinine – CKD3 | Serum creatinine in the last 6 months for patients with CKD stage 3. |
CQCDOAC004B | 6-month CrCl – CKD3, with valid weight + creatinine | CrCl in the last 6 months, plus weight in the last 12 months and serum creatinine in the last 6 months. |
CQCDOAC005 | Annual haemoglobin | Hb checked in the last 12 months. |
CQCDOAC006 | Review – severely low haemoglobin | Patients whose most recent Hb is below 90 g/L have had an anticoagulation review since that Hb result. |
CQCDOAC007 | Appropriate kidney function | Latest creatinine clearance is in safe range for the drug: ≥ 30 if on dabigatran, ≥ 15 otherwise. |
⚠️ The naming pattern across the DOAC suite is:
plain number = creatinine clearance
A = serum creatinine
B = creatinine clearance with up-to-date weight and creatinine.
Patients only appear in B-version denominators once both supporting values are on file.
CQCWARFARIN001–002 — Warfarin Monitoring
Indicator | Description | What It Checks |
CQCWARFARIN001 | INR monitoring | INR in the last 3 months, or a self-monitoring code in the last 12 months. |
CQCWARFARIN002 | Review – high INR | Patients with a worrying INR result in the last 6 months — either one INR ≥ 8 or two or more INR ≥ 5 — have had an anticoagulation review since that result. |
CQCMETFORMIN001–002 — Metformin Monitoring
Indicator | Description | What It Checks |
CQCMETFORMIN001 | Kidney function – metformin | eGFR in the last 12 months. |
CQCMETFORMIN002 | Satisfactory kidney function – metformin | Of metformin patients with an eGFR in the last 12 months, the proportion whose most recent eGFR is ≥ 30 (i.e., kidney function is still within safe range for metformin). |
CQCAMIODERONE001 — Amiodarone Monitoring
Indicator | Description | What It Checks |
CQCAMIODERONE001 | Function checks – amiodarone | U&Es, LFTs and TFTs all in the last 6 months. |
CQCLI001–002 — Lithium Monitoring
Indicator | Description | What It Checks |
CQCLI001 | Serum lithium level | Lithium level checked in the last 3 months. |
CQCLI002 | Ca, kidney, and thyroid monitoring | Calcium, U&Es and TFTs all in the last 6 months. |
💉 DMARDs Indicators
CQCMET001 / CQCLEF001 / CQCAZA001 — DMARD Monitoring
Indicator | Description | What It Checks |
CQCMET001 | Methotrexate monitoring | FBC, U&Es and LFTs all in the last 12 weeks. |
CQCLEF001 | Leflunomide monitoring | FBC, U&Es, LFTs, BP and weight all in the last 12 weeks. |
CQCAZA001 | Azathioprine monitoring | FBC, U&Es and LFTs all in the last 12 weeks. |
CQCACEARB001 / CQCALDANT001 — Heart & Kidney Function Monitoring
Indicator | Description | What It Checks |
CQCACEARB001 | Kidney function – ACEi/ARB | Creatinine or eGFR in the last 12 months. |
CQCALDANT001 | Kidney function – heart failure (aldosterone antagonists) | Patients on an aldosterone antagonist who have a current heart failure diagnosis have had a creatinine or eGFR in the last 6 months. (Excludes patients whose HF has been coded as resolved.) |
🔍 Missed Diagnoses Indicators
CQC_MISDIAG_CKD / CQC_MISDIAG_DM — Case-finding for undiagnosed conditions
Indicator | Description | What It Checks |
CQC_MISDIAG_CKD | Possible undiagnosed CKD | Patients who appear to meet CKD diagnostic criteria from their blood results but do not have a coded CKD diagnosis. |
CQC_MISDIAG_DM | Possible undiagnosed diabetes | Patients who appear to meet diabetes diagnostic criteria from their blood results but do not have a coded diabetes diagnosis. |
🛑 Drug Safety Alert Indicators
CQCSAFETYALERT001–010 — MHRA / drug-safety reviews
These indicators identify patients on high-risk medications or combinations that require a documented medication review or safety information record.
Indicator | Description | What It Checks |
CQCSAFETYALERT001 | Hydrochlorothiazide – skin cancer information | Confirms that patients on hydrochlorothiazide have received skin cancer risk information. |
CQCSAFETYALERT002 | High-dose SSRI in older adults – review | Patients aged 65+ on high-dose SSRI have had a medication review. |
CQCSAFETYALERT003 | Clopidogrel + PPI – review | Patients co-prescribed clopidogrel and a PPI have had a medication review. |
CQCSAFETYALERT004 | Febuxostat with CVD – review | Patients on febuxostat with cardiovascular disease have had a medication review. |
CQCSAFETYALERT005 | New fentanyl patch without prior opioid – review | Patients started on a fentanyl patch in the last year without prior opioid exposure have had a medication review. |
CQCSAFETYALERT006 | Mirabegron – BP monitoring | Patients on mirabegron have had blood pressure monitoring. |
CQCSAFETYALERT008 | SGLT-2 inhibitors – safety education | Patients on SGLT-2 inhibitors have received ketoacidosis and Fournier's gangrene education. |
CQCSAFETYALERT009 | Simvastatin 40/80mg + CYP3A4-inhibiting CCB – review | Patients on simvastatin 40mg or 80mg co-prescribed a CYP3A4-inhibiting calcium channel blocker have had a medication review. |
CQCSAFETYALERT010 | Teratogenic drugs in women of childbearing potential – review | Women of childbearing potential on teratogenic drugs have had a medication review. |
💡 Why These Indicators Matter
CQC indicators help practices:
Stay compliant with medicines safety and CQC standards
Identify patients overdue for essential blood monitoring
Ensure safe prescribing for high-risk or renal-dependent drugs
Provide clear audit evidence for regulators and PCNs
🧭 Where to Find Them in Hippo
You can find CQC indicators in:
Recall Campaign setup → under the “CQC” framework
Indicator Performance dashboard → to monitor completion and progress